531 related articles for article (PubMed ID: 16966581)
1. Central action of increased osmolality to support blood pressure in deoxycorticosterone acetate-salt rats.
O'Donaughy TL; Qi Y; Brooks VL
Hypertension; 2006 Oct; 48(4):658-63. PubMed ID: 16966581
[TBL] [Abstract][Full Text] [Related]
2. Deoxycorticosterone acetate-salt rats: hypertension and sympathoexcitation driven by increased NaCl levels.
O'Donaughy TL; Brooks VL
Hypertension; 2006 Apr; 47(4):680-5. PubMed ID: 16520400
[TBL] [Abstract][Full Text] [Related]
3. Contribution of central nitric oxide to the regulation of blood pressure and sodium balance in DOCA-salt hypertension.
Seto S; Nagao S; Ozeki S; Tetsuo H; Akahoshi M; Yano K
J Cardiovasc Pharmacol; 2006 May; 47(5):680-5. PubMed ID: 16775508
[TBL] [Abstract][Full Text] [Related]
4. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
Nishimura M; Ohtsuka K; Sakamoto M; Nanbu A; Takahashi H; Yoshimura M
J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
[TBL] [Abstract][Full Text] [Related]
5. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension.
Fernandes S; Bruneval P; Hagege A; Heudes D; Ghostine S; Bouby N
Endocrinology; 2002 Jul; 143(7):2759-66. PubMed ID: 12072411
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
[TBL] [Abstract][Full Text] [Related]
7. Effect of an ET(B)-selective and a mixed ET(A/B) endothelin receptor antagonist on venomotor tone in deoxycorticosterone-salt hypertension.
Johnson RJ; Galligan JJ; Fink GD
J Hypertens; 2001 Mar; 19(3):431-40. PubMed ID: 11288813
[TBL] [Abstract][Full Text] [Related]
8. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension.
Fink GD; Johnson RJ; Galligan JJ
Hypertension; 2000 Jan; 35(1 Pt 2):464-9. PubMed ID: 10642342
[TBL] [Abstract][Full Text] [Related]
10. 5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats.
Diaz J; Ni W; Thompson J; King A; Fink GD; Watts SW
J Pharmacol Exp Ther; 2008 Jun; 325(3):1031-8. PubMed ID: 18305011
[TBL] [Abstract][Full Text] [Related]
11. Role of endothelin and vasopressin in DOCA-salt hypertension.
Yu M; Gopalakrishnan V; McNeill JR
Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
[TBL] [Abstract][Full Text] [Related]
12. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats.
Intengan HD; He G; Schiffrin EL
Hypertension; 1998 Oct; 32(4):770-7. PubMed ID: 9774378
[TBL] [Abstract][Full Text] [Related]
13. Paraventricular nucleus lesions attenuate the development of hypertension in DOCA/salt-treated rats.
Nakata T; Takeda K; Itho H; Hirata M; Kawasaki S; Hayashi J; Oguro M; Sasaki S; Nakagawa M
Am J Hypertens; 1989 Aug; 2(8):625-30. PubMed ID: 2570597
[TBL] [Abstract][Full Text] [Related]
14. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats.
Watts SW; Fink GD
Am J Physiol; 1999 Mar; 276(3):H944-52. PubMed ID: 10070078
[TBL] [Abstract][Full Text] [Related]
15. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats.
Maeda C; Schaan B; Oliveira E; Oliveira V; De Angelis K; Irigoyen M
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of magnocellular vasopressin mRNA in rats with deoxycorticosterone-acetate induced salt appetite.
Grillo CA; Saravia F; Ferrini M; Piroli G; Roig P; García SI; de Kloet ER; De Nicola AF
Neuroendocrinology; 1998 Aug; 68(2):105-15. PubMed ID: 9705577
[TBL] [Abstract][Full Text] [Related]
17. Contribution of vascular and tubular effects of arginine-vasopressin to the development of deoxycorticosterone acetate (DOCA)-salt hypertension in rats.
Hofbauer KG; Mah SC; Wood JM; Baum HP; Hänni H; Opperman JR; Kraetz J
J Hypertens Suppl; 1984 Dec; 2(3):S333-5. PubMed ID: 6599676
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal-induced antihypertensive effect of vasopressin in Doca-salt hypertension.
Chiu EK; McNeill JR
Am J Hypertens; 1989 Jun; 2(6 Pt 1):458-61. PubMed ID: 2757802
[TBL] [Abstract][Full Text] [Related]
19. Activation of vascular BK channel by tempol in DOCA-salt hypertensive rats.
Xu H; Bian X; Watts SW; Hlavacova A
Hypertension; 2005 Nov; 46(5):1154-62. PubMed ID: 16216988
[TBL] [Abstract][Full Text] [Related]
20. Reduced contractile sensitivity and vasopressin receptor affinity in DOCA-salt hypertension.
Bockman CS; Jeffries WB; Pettinger WA; Abel PW
Am J Physiol; 1992 Jun; 262(6 Pt 2):H1752-8. PubMed ID: 1535757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
